bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S9 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S9. The ROC curves for the establishing process of the APL9 score. The ROCs of the randomized 10 models in each training set (A) and validation set (B). The shadow indicates the 500-bootstrap confidence intervals of APL9 score. ROC, receiver operating characteristic.
Supplemental Figure 2 from Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses
Authors: Aggen David H. , Ager Casey R. , Obradovic Aleksandar Z. , Chowdhury Nivedita , Ghasemzadeh Ali , Mao Wendy , Chaimowitz Matthew G. , Lopez-Bujanda Zoila A. , Spina Catherine S. , Hawley Jessica E. , Dallos Matthew C. , Zhang Cheng , Wang Vinson , Li Hu , Guo Xinzheng V. , Drake Charles G.
Published: April 2023

Comparison of combination anti-PD1/anti-IL1b and cabozantinib/anti-IL1b treatment.
Figure S8 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S8. Spearman's correlation between the gene expression (x axis) and methylation level (y axis) at different regions of GATA1 in patients with APL from the The Cancer Genome Atlas (TCGA) dataset (n = 15). P-values are indicated on each panel. The line shown is a y~x regression line, and the shaded regions are the 95% confidence intervals for the slope of the line.
Figure S5 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S5. Unsupervised hierarchical clustering of the global gene expression profile from 323 patients with APL. Genes and samples are clustered using the ward.D method, and distances are calculated on the basis of the Pearson's correlation coefficient. Columns indicate patients with APL and rows indicate genes.
Figure S4 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S4. Functional gene categories among different Sanz risk groups and pairwise co-occurrence and mutual exclusivity analysis. (A) Different distributions of mutations of known functional gene groups among the Sanz risk groups. (B) Co-occuring and mutually exclusive mutations in genes with a mutational frequency > 2%. P-value is calculated using the Fisher's exact test. *P < 0.05, **P < 0.01, ***P < 0.001.
Supplementary Table 1 from Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Authors: Gao ChongFeng , Wisniewski Luke , Liu Ying , Staal Ben , Beddows Ian , Plenker Dennis , Aldakkak Mohammed , Hall Johnathan , Barnett Daniel , Gouda Mirna Kheir , Allen Peter , Drake Richard , Zureikat Amer , Huang Ying , Evans Douglas , Singhi Aatur , Brand Randall E. , Tuveson David A. , Tsai Susan , Haab Brian B.
Published: April 2023

Gene-expression analyses
Figure S3 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S3. Genes newly found in APL and pairwise comparison among Sanz risk groups. (A) Schematic representation of three genes newly found in APL. (B) Genes with significant differences in the pairwise comparison among Sanz risk groups. P-value is calculated using the Fisher's exact test
Figure S2 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S2. Summary of somatic mutations in 348 patients with primary APL detected using whole-exome sequencing, whole-genome sequencing, and RNA sequencing. (A) The number of different variant classifications. (B) The number of different variant types. (C) The number of variants per sample. (D) The number of SNVs class. SNVs, single-nucleotide variations; INSs, insertions; DELs, deletions.
Figure S16 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S16. External validation of the TCGA cohort. (A) The upper panel shows the expression patterns of 9 APL9-related genes from 14 TCGA patients with APL and the bottom panel shows the bar plot of the APL9 score, in ascending order. (B) Kaplan-Meier estimates of OS according to the APL9 score groups in the TCGA cohort. (C) ROC curve of the revised risk score to predict the OS status in the TCGA cohort. (D) Kaplan-Meier estimates of OS according to revised risk group in the TCGA cohort. P-value is calculated using the log-rank test. OS, overall survival; TCGA, The Cancer Genome Atlas; HR, high-risk; SR, standard-risk; ROC, receiver operating characteristic.
Supplementary Figures S1-S6 from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Authors: Hitchman Tyler D. , Bayshtok Gabriella , Ceraudo Emilie , Moore Amanda R. , Lee Cindy , Jia Ruobing , Wang Naitao , Pachai Mohini R. , Shoushtari Alexander N. , Francis Jasmine H. , Guan Youxin , Chen Juliet , Chang Matthew T. , Taylor Barry S. , Sakmar Thomas P. , Huber Thomas , Chi Ping , Chen Yu
Published: April 2023

Supplementary figures S1-S6 with figure legends.
Figure S15 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S15. Kaplan-Meier plots of Combined Sanz groups and ROC plots between the Sanz score and the revised risk score. Kaplan-Meier estimates of OS (A), EFS (B), and DFS (C) when combining the Sanz low- and intermediate-risk into a single category. Comparision of the OS (D), EFS (E), and DFS (F) ROC curves between the Sanz score and the revised model score. P-value is calculated using the log-rank test. OS, overall survival; EFS, event-free survival; DFS, disease-free survival; ROCï¼Œreceiver operating characteristic.
Figure S12 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S12. The agreement between the predicted and the actual EFS of the new score system. The 1000-sample bootstrapped calibration plots at 1-year (A), 2-year (B), and 5-year (C) of the integrated model by using white blood cell count, APL9 score, and NRAS mutations
Figure S11 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S11. Relative mRNA expression levels of the 9 genes. The relative mRNA expression levels of the GATA1, CLCN4, CACNA2D2, OPTN, KRT1, LTF, S100A12, LEF1, and LGALS1 between different APL9 score groups. Values are the means {plus minus} s.e. .
Supplementary Table S3 from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Authors: Parikh Aparna R. , Mojtahed Amikasra , Schneider Jaime L. , Kanter Katie , Van Seventer Emily E. , Fetter Isobel J. , Thabet Ashraf , Fish Madeleine G. , Teshome Bezaye , Fosbenner Kathryn , Nadres Brandon , Shahzade Heather A. , Allen Jill N. , Blaszkowsky Lawrence S. , Ryan David P. , Giantonio Bruce , Goyal Lipika , Nipp Ryan D. , Roeland Eric , Weekes Colin D. , Wo Jennifer Y. , Zhu Andrew X. , Dias-Santagata Dora , Iafrate A. John , Lennerz Jochen K. , Hong Theodore S. , Siravegna Giulia , Horick Nora , Clark Jeffrey W. , Corcoran Ryan B.
Published: April 2023

Supplementary Table S3
Supplementary Table S2 from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Authors: Parikh Aparna R. , Mojtahed Amikasra , Schneider Jaime L. , Kanter Katie , Van Seventer Emily E. , Fetter Isobel J. , Thabet Ashraf , Fish Madeleine G. , Teshome Bezaye , Fosbenner Kathryn , Nadres Brandon , Shahzade Heather A. , Allen Jill N. , Blaszkowsky Lawrence S. , Ryan David P. , Giantonio Bruce , Goyal Lipika , Nipp Ryan D. , Roeland Eric , Weekes Colin D. , Wo Jennifer Y. , Zhu Andrew X. , Dias-Santagata Dora , Iafrate A. John , Lennerz Jochen K. , Hong Theodore S. , Siravegna Giulia , Horick Nora , Clark Jeffrey W. , Corcoran Ryan B.
Published: April 2023

Supplementary Table S2
Supplementary Figure S7 from Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions
Authors: Rickelt Steffen , Condon Charlene , Mana Miyeko , Whittaker Charlie , Pfirschke Christina , Roper Jatin , Patil Deepa T. , Brown Ian , Mattia Anthony R. , Zukerberg Lawrence , Zhao Qing , Chetty Runjan , Lauwers Gregory Y. , Neyaz Azfar , Leijssen Lieve G.J. , Boylan Katherine , Yilmaz Omer H. , Deshpande Vikram , Hynes Richard O.
Published: April 2023

AGRN staining in muscularis mucosae scored by non-pathologists.
Supplementary Figure S5 from Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy
Authors: Chen Jingwei , Nelson Christopher , Wong Matthew , Tee Andrew E. , Liu Pei Y. , La Ting , Fletcher Jamie I. , Kamili Alvin , Mayoh Chelsea , Bartenhagen Christoph , Trahair Toby N. , Xu Ning , Jayatilleke Nisitha , Wong Marie , Peng Hui , Atmadibrata Bernard , Cheung Belamy B. , Lan Qing , Bryan Tracy M. , Mestdagh Pieter , Vandesompele Jo , Combaret Valerie , Boeva Valentina , Wang Jenny Y. , Janoueix-Lerosey Isabelle , Cowley Mark J. , MacKenzie Karen L. , Dolnikov Alla , Li Jinyan , Polly Patsie , Marshall Glenn M. , Reddel Roger R. , Norris Murray D. , Haber Michelle , Fischer Matthias , Zhang Xu D. , Pickett Hilda A. , Liu Tao
Published: April 2023

Supplementary Figure S5. BET bromodomain inhibitors and proteasome inhibitors exert synergistic anticancer effects against TERT-rearranged neuroblastoma cells.
Supplementary Figure S5 from Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions
Authors: Rickelt Steffen , Condon Charlene , Mana Miyeko , Whittaker Charlie , Pfirschke Christina , Roper Jatin , Patil Deepa T. , Brown Ian , Mattia Anthony R. , Zukerberg Lawrence , Zhao Qing , Chetty Runjan , Lauwers Gregory Y. , Neyaz Azfar , Leijssen Lieve G.J. , Boylan Katherine , Yilmaz Omer H. , Deshpande Vikram , Hynes Richard O.
Published: April 2023

AGRN is predominantly synthesized by epithelial cells and deposited into the muscularis mucosa.
Supplementary table 1 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Authors: Thakur Shilpa , Daley Brianna , Millo Corina , Cochran Craig , Jacobson Orit , Lu Huiyan , Wang Zhantong , Kiesewetter Dale , Chen Xiaoyuan , Vasko Vasyl , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplemental Table 1: Analysis of immunostaining of SSTR2 in human tissue samples derived from thyroid cancer patients. Score 0-no staining, Score 1-positive staining in <25% of cells, Score 2-positive staining in 25-50% of cells, Score 3-positive staining in >50% of cells. PTC - papillary thyroid cancer, FTC - follicular thyroid cancer, PDTC - poorly differentiated thyroid cancer, MTC - medullary thyroid cancer, HTC - Hürthle cell thyroid cancer.
Supplementary Figure 8 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Authors: Thakur Shilpa , Daley Brianna , Millo Corina , Cochran Craig , Jacobson Orit , Lu Huiyan , Wang Zhantong , Kiesewetter Dale , Chen Xiaoyuan , Vasko Vasyl , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplementary figure 8. Experimental design of mice studies. (A) Flow diagram depicts an experimental strategy for PET imaging with different SST analogs in tumor mice models. (B) Flow diagram depicts an experimental strategy for 177Lu-DOTA-EB-TATE therapy in mice models characterized by high- and low- SSTR2 expression and similar tumor growth rate. (C) Flow diagram depicts an experimental strategy involving treatment with different 177Lu-labeled SST analogs in a mice model characterized by high- SSTR2 expression.
Supplementary Figure 5 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Authors: Thakur Shilpa , Daley Brianna , Millo Corina , Cochran Craig , Jacobson Orit , Lu Huiyan , Wang Zhantong , Kiesewetter Dale , Chen Xiaoyuan , Vasko Vasyl , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplemental figure 5: Decitabine (DEC) treatment did not improve the uptake of 86Y-DOTA-EB-TATE in the tumors of the mice models. (A) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and decitabine (DEC) treated FTC133 subcutaneous mice model. The bar graph shows no significant difference in the uptake of 86Y-DOTA-EB-TATE between the control (n=3) and DEC (n=3) treated mice. (B) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and DEC treated AR42J subcutaneous mice model. The bar graph shows no significant difference in the uptake of 86Y-DOTA-EB-TATE between the control (n=5) and DEC (n=3) treated mice. Tumors (Tu) are indicated by white arrows.
Supplementary Figure 4 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Authors: Thakur Shilpa , Daley Brianna , Millo Corina , Cochran Craig , Jacobson Orit , Lu Huiyan , Wang Zhantong , Kiesewetter Dale , Chen Xiaoyuan , Vasko Vasyl , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplemental figure 4: VAC treatment did not improve the uptake of SST analogs in the tumors of the mice models. (A) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and VAC treated FTC133 subcutaneous mice model. The bar graph shows no significant difference in the uptake of 68Ga-DOTA-TATE, 68Ga-DOTA-JR11 and 86Y-DOTA-EB-TATE between the control (n=5) and VAC (n=5) treated mice. The representative immunohistochemistry images show an increased cytoplasmic expression of SSTR2 in the tumors of the VAC treated mice in comparison to the tumors of the control mice (Supplemental Table 2). (B) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and VAC treated FTC133 metastatic mice model. The bar graph shows no significant difference in the uptake of 68Ga-DOTA-TATE, 68Ga-DOTA-JR11 and 86Y-DOTA-EB-TATE between the control (n=8-12) and VAC (n=8-12) treated mice. The immunohistochemistry images show no difference in the expression of SSTR2 in the metastatic tumors of the control and VAC treated FTC133 mice (Supplemental Table 2). (C) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and VAC treated TT subcutaneous mice model. The bar graph shows no significant difference in the uptake of 68Ga-DOTA-TATE, 68Ga-DOTA-JR11 and 86Y-DOTA-EB-TATE between the control (n=5) and VAC (n=5) treated mice. The representative immunohistochemistry images show no difference in the expression of SSTR2 within the tumors of the control and VAC treated mice (Supplemental Table 2). (D) Representative PET images comparing the uptake of 86Y-DOTA-EB-TATE between the control and VAC treated AR42J subcutaneous mice model. The bar graph shows no significant difference in the uptake of 68Ga-DOTA-TATE, 68Ga-DOTA-JR11 and 86Y-DOTA-EB-TATE between the control (n=4) and VAC (n=5) treated mice. The representative immunohistochemistry images show an increased expression of SSTR2 in the tumors of the VAC treated mice in comparison to the tumors of the control mice (Supplemental Table 2). Tumors (Tu) and metastasis (Met) are indicated by white arrows. The SUV scales range from 0 to 3 for 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 and 0 to 15 for 86Y-DOTA-EB-TATE. Data are presented as mean{plus minus}SD.
Supplementary Figure 1 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Authors: Thakur Shilpa , Daley Brianna , Millo Corina , Cochran Craig , Jacobson Orit , Lu Huiyan , Wang Zhantong , Kiesewetter Dale , Chen Xiaoyuan , Vasko Vasyl , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplemental figure 1: SSTR2 is overexpressed in thyroid cancer tissues in comparison to normal thyroid tissues. (A) SSTR2 expression in different stages of PTC. (B) SSTR2 expression in histological subtypes of PTC. (C) Comparison of SSTR2 mRNA expression in different TC cell lines. (D) TT cells had significantly higher expression than BCPAP and FTC133 cells at the mRNA level. *p<0.05, ***p<0.001.
Supplementary Table S7 from Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of Head and Neck Squamous Cell Carcinoma
Authors: Holt Jeremiah , Walter Vonn , Yin Xiaoying , Marron David , Wilkerson Matthew D. , Choi Hyo Young , Zhao Xiaobei , Jo Heejoon , Hayes David Neil , Ko Yoon Ho
Published: April 2023

REporting recommendations for tumour MARKer prognostic studies (REMARK) checklist.
Supplementary Table 4 from Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Authors: Jiffry Jeeshan , Thavornwatanayong Thongthai , Rao Devika , Fogel Elisha J. , Saytoo Durvanand , Nahata Rishika , Guzik Hillary , Chaudhary Imran , Augustine Titto , Goel Sanjay , Maitra Radhashree
Published: April 2023

Supplementary Table 4 from Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Supplementary Table 3 from Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Authors: Jiffry Jeeshan , Thavornwatanayong Thongthai , Rao Devika , Fogel Elisha J. , Saytoo Durvanand , Nahata Rishika , Guzik Hillary , Chaudhary Imran , Augustine Titto , Goel Sanjay , Maitra Radhashree
Published: April 2023

Supplementary Table 3 from Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Supplementary Table 1 from Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Authors: Jiffry Jeeshan , Thavornwatanayong Thongthai , Rao Devika , Fogel Elisha J. , Saytoo Durvanand , Nahata Rishika , Guzik Hillary , Chaudhary Imran , Augustine Titto , Goel Sanjay , Maitra Radhashree
Published: April 2023

Supplementary Table 1 from Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Supplementary Figure 2 from Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Authors: Jiffry Jeeshan , Thavornwatanayong Thongthai , Rao Devika , Fogel Elisha J. , Saytoo Durvanand , Nahata Rishika , Guzik Hillary , Chaudhary Imran , Augustine Titto , Goel Sanjay , Maitra Radhashree
Published: April 2023

Supplementary Figure 2: A) Gene expression in control patients: 14 autophagy gene transcripts which were significantly upregulated in experimental patient group were not significant in control group. B) Table detailing the p values and expression levels of the 14 gene transcripts.
Supplementary Figure 1 from Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Authors: Jiffry Jeeshan , Thavornwatanayong Thongthai , Rao Devika , Fogel Elisha J. , Saytoo Durvanand , Nahata Rishika , Guzik Hillary , Chaudhary Imran , Augustine Titto , Goel Sanjay , Maitra Radhashree
Published: April 2023

Supplementary Fig 1: STRING clustering analysis of 88 autophagic genes under study to evaluate the strength of interactions among genes. The altered genes (ATG16L1, ATG3, ATG7, DRAM1, MAP1LC3A, SQSTM1, ULK3, UVRAG) are central in the pathway
Supplementary Table S1 from Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of Head and Neck Squamous Cell Carcinoma
Authors: Holt Jeremiah , Walter Vonn , Yin Xiaoying , Marron David , Wilkerson Matthew D. , Choi Hyo Young , Zhao Xiaobei , Jo Heejoon , Hayes David Neil , Ko Yoon Ho
Published: April 2023

Baseline clinicopathological characteristics of patients with HNSCC in UNC and TCGA data sets.
Supplementary Results from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer
Authors: Malla Sudhir B. , Fisher David J. , Domingo Enric , Blake Andrew , Hassanieh Sylvana , Redmond Keara L. , Richman Susan D. , Youdell Michael , Walker Steven M. , Logan Gemma E. , Chatzipli Aikaterina , Amirkhah Raheleh , Humphries Matthew P. , Craig Stephanie G. , McDermott Ultan , Seymour Matthew T. , Morton Dion G. , Quirke Philip , West Nicholas P. , Salto-Tellez Manuel , Kennedy Richard D. , Johnston Patrick G. , Tomlinson Ian , Koelzer Viktor H. , Campo Letitia , Kaplan Richard S. , Longley Daniel B. , Lawler Mark , Maughan Timothy S. , Brown Louise C. , Dunne Philip D.
Published: April 2023

Supplementary Results
Supplementary Figure legends from Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
Authors: Zhang Li , Meng Li , Liu Bingcheng , Zhang Yanli , Zhu Huanling , Cui Jiuwei , Sun Aining , Hu Yu , Jin Jie , Jiang Hao , Zhang Xi , Li Yan , Liu Li , Zhang Wanggang , Liu Xiaoli , Gu Jian , Qiao Jianhui , Ouyang Guifang , Liu Xin , Luo Jianmin , Jiang Ming , Xie Xiaobao , Li Jianyong , Zhao Chunting , Zhang Mei , Yang Tonghua , Wang Jianxiang
Published: April 2023

Supplementary Figure legends
Supplementary Fig. S4 from Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
Authors: Zhang Li , Meng Li , Liu Bingcheng , Zhang Yanli , Zhu Huanling , Cui Jiuwei , Sun Aining , Hu Yu , Jin Jie , Jiang Hao , Zhang Xi , Li Yan , Liu Li , Zhang Wanggang , Liu Xiaoli , Gu Jian , Qiao Jianhui , Ouyang Guifang , Liu Xin , Luo Jianmin , Jiang Ming , Xie Xiaobao , Li Jianyong , Zhao Chunting , Zhang Mei , Yang Tonghua , Wang Jianxiang
Published: April 2023

AEs of interest and laboratory abnormalities: Forest plot comparing rate differences (all grades) for flumatinib and imatinib. AEs were assessed according to the Common Terminology Criteria for Adverse. Events (NCI-CTCAE version 4.03). Abbreviation: QTc, Electrocardiogram QT corrected interval.
Supplementary Fig. S2 from Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
Authors: Zhang Li , Meng Li , Liu Bingcheng , Zhang Yanli , Zhu Huanling , Cui Jiuwei , Sun Aining , Hu Yu , Jin Jie , Jiang Hao , Zhang Xi , Li Yan , Liu Li , Zhang Wanggang , Liu Xiaoli , Gu Jian , Qiao Jianhui , Ouyang Guifang , Liu Xin , Luo Jianmin , Jiang Ming , Xie Xiaobao , Li Jianyong , Zhao Chunting , Zhang Mei , Yang Tonghua , Wang Jianxiang
Published: April 2023

MMR or CCyR rate difference for patients receiving flumatinib versus imatinib by Sokal risk-group. Black round = rate difference, black error bars = 95% confidence interval. Abbreviation: CI, confidence interval.
Supplementary fig 5 from High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors
Authors: Lin Lin , Kane Nathanael , Kobayashi Naoko , Kono Evelyn A. , Yamashiro Joyce M. , Nickols Nicholas G. , Reiter Robert E.
Published: April 2023

Supplemental 5. anti-Gr-1 increased PD-1 expression.
Supplementary Fig. S1 from Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
Authors: Zhang Li , Meng Li , Liu Bingcheng , Zhang Yanli , Zhu Huanling , Cui Jiuwei , Sun Aining , Hu Yu , Jin Jie , Jiang Hao , Zhang Xi , Li Yan , Liu Li , Zhang Wanggang , Liu Xiaoli , Gu Jian , Qiao Jianhui , Ouyang Guifang , Liu Xin , Luo Jianmin , Jiang Ming , Xie Xiaobao , Li Jianyong , Zhao Chunting , Zhang Mei , Yang Tonghua , Wang Jianxiang
Published: April 2023

CONSORT diagram for the FESTnd study.
Supplementary fig 4 from High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors
Authors: Lin Lin , Kane Nathanael , Kobayashi Naoko , Kono Evelyn A. , Yamashiro Joyce M. , Nickols Nicholas G. , Reiter Robert E.
Published: April 2023

Supplemental 4. anti-Gr-1 eradiated MDSC in spleen, blood and tumor.
Supplementary Data from Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary
Authors: Raghav Kanwal , Hwang Hyunsoo , Jácome Alexandre A. , Bhang Eric , Willett Anneleis , Huey Ryan W. , Dhillon Nishat P. , Modha Jignesh , Smaglo Brandon , Matamoros Aurelio , Estrella Jeannelyn S. , Jao Justin , Overman Michael J. , Wang Xuemei , Greco F. Anthony , Loree Jonathan M. , Varadhachary Gauri R.
Published: April 2023

Supplementary Data
Figure S3 from Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection
Authors: Jolissaint Joshua S. , Soares Kevin C. , Seier Kenneth P. , Kundra Ritika , Gönen Mithat , Shin Paul J. , Boerner Thomas , Sigel Carlie , Madupuri Ramyasree , Vakiani Efsevia , Cercek Andrea , Harding James J. , Kemeny Nancy E. , Connell Louise C. , Balachandran Vinod P. , D'Angelica Michael I. , Drebin Jeffrey A. , Kingham T. Peter , Wei Alice C. , Jarnagin William R.
Published: April 2023

Figure S3
Figure S1 from Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection
Authors: Jolissaint Joshua S. , Soares Kevin C. , Seier Kenneth P. , Kundra Ritika , Gönen Mithat , Shin Paul J. , Boerner Thomas , Sigel Carlie , Madupuri Ramyasree , Vakiani Efsevia , Cercek Andrea , Harding James J. , Kemeny Nancy E. , Connell Louise C. , Balachandran Vinod P. , D'Angelica Michael I. , Drebin Jeffrey A. , Kingham T. Peter , Wei Alice C. , Jarnagin William R.
Published: April 2023

Figure S1
Figure S2 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

Kaplan-Meier (KM) analyses by HPV, DeepPET-OPSCC risk category, entire cohort
Table S4 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Authors: Adib Elio , Klonowska Katarzyna , Giannikou Krinio , Do Khanh T. , Pruitt-Thompson Solida , Bhushan Ketki , Milstein Matthew I. , Hedglin Jennifer , Kargus Katherine E. , Sholl Lynette M. , Tsuji Junko , Hyman David M. , Sisk Anne , Shapiro Geoffrey I. , Vargas Hebert A. , Harding James J. , Voss Martin H. , Iyer Gopa , Kwiatkowski David J.
Published: April 2023

Table S4. Inactivating mutations in TSC1/TSC2 and activating mutation in MTOR identified in 30 patients in the clinical trial - clonality and biallelic TSC1/TSC2 inactivation status.
Table S1 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Authors: Adib Elio , Klonowska Katarzyna , Giannikou Krinio , Do Khanh T. , Pruitt-Thompson Solida , Bhushan Ketki , Milstein Matthew I. , Hedglin Jennifer , Kargus Katherine E. , Sholl Lynette M. , Tsuji Junko , Hyman David M. , Sisk Anne , Shapiro Geoffrey I. , Vargas Hebert A. , Harding James J. , Voss Martin H. , Iyer Gopa , Kwiatkowski David J.
Published: April 2023

Table S1. Massively Parallel Sequencing (MPS) metrics and cancer sample characteristics.
Figure S14 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

Scatter plots, SUVmax/MTV and DeepPET-OPSCC scores, entire cohort
Fig S1 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Authors: Adib Elio , Klonowska Katarzyna , Giannikou Krinio , Do Khanh T. , Pruitt-Thompson Solida , Bhushan Ketki , Milstein Matthew I. , Hedglin Jennifer , Kargus Katherine E. , Sholl Lynette M. , Tsuji Junko , Hyman David M. , Sisk Anne , Shapiro Geoffrey I. , Vargas Hebert A. , Harding James J. , Voss Martin H. , Iyer Gopa , Kwiatkowski David J.
Published: April 2023

Fig S1. A. Treatment duration and clinical events for four subjects with clinical benefit. In the swimmer plot, patients are deceased at last follow-up unless indicated by the arrowhead. Abbreviations: LMS - leiomyosarcoma; UTUC - upper tract urothelial carcinoma; SCC - squamous cell carcinoma. B-C. Kaplan Meier curves for progression-free survival (B) and overall survival (C).
Figure S12 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

KM analyses, DeepPET-OPSCC risk category with five groups, discovery cohort
Figure S1 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

Risk distribution of DeepPET-OPSCC score
Figure S1 from Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Authors: Do Khanh T. , Kochupurakkal Bose , Kelland Sarah , de Jonge Adrienne , Hedglin Jennifer , Powers Allison , Quinn Nicholas , Gannon Courtney , Vuong Loan , Parmar Kalindi , Lazaro Jean-Bernard , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Consort Diagram
Supplementary figure SF1 from Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
Authors: Turner Philip G. , Jain Suneil , Cole Aidan , Grey Arthur , Mitchell Darren , Prise Kevin M. , Hounsell Alan R. , McGarry Conor K. , Biggart Sandra , O'Sullivan Joe M.
Published: April 2023

Supplementary figure SF1 shows CONSORT diagram of trial profile
Supplementary Table S4 from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Authors: Chida Keigo , Kawazoe Akihito , Kawazu Masahito , Suzuki Toshihiro , Nakamura Yoshiaki , Nakatsura Tetsuya , Kuwata Takeshi , Ueno Toshihide , Kuboki Yasutoshi , Kotani Daisuke , Kojima Takashi , Taniguchi Hiroya , Mano Hiroyuki , Ikeda Masafumi , Shitara Kohei , Endo Itaru , Yoshino Takayuki
Published: April 2023

Patient characteristics according to PTEN mutational status
Supplementary Table S3 from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Authors: Chida Keigo , Kawazoe Akihito , Kawazu Masahito , Suzuki Toshihiro , Nakamura Yoshiaki , Nakatsura Tetsuya , Kuwata Takeshi , Ueno Toshihide , Kuboki Yasutoshi , Kotani Daisuke , Kojima Takashi , Taniguchi Hiroya , Mano Hiroyuki , Ikeda Masafumi , Shitara Kohei , Endo Itaru , Yoshino Takayuki
Published: April 2023

Univariate and multivariate analysis of OS according to TMB and clinical features
Supplementary Table S8 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Table S8 presents results of the multivariate analysis on disease-specific survival on cohort II.
Supplementary Table S7 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Table S7 presents summary statistics estimated by immunofluorescence for relevant cell phenotype.
Supplementary Figure S4 from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Authors: Chida Keigo , Kawazoe Akihito , Kawazu Masahito , Suzuki Toshihiro , Nakamura Yoshiaki , Nakatsura Tetsuya , Kuwata Takeshi , Ueno Toshihide , Kuboki Yasutoshi , Kotani Daisuke , Kojima Takashi , Taniguchi Hiroya , Mano Hiroyuki , Ikeda Masafumi , Shitara Kohei , Endo Itaru , Yoshino Takayuki
Published: April 2023

Gene set enrichment analysis of whole transcriptome expression (A) and (B): GSEA enrichment plot for "HALLMARK_PI3K_AKT_MTOR_SIGNALING" and "HALLMARK_MTORC1_SIGNALING" between mutant PTEN/mutations in the phosphatase domain and wild-type PTEN (C) and (D): GSEA enrichment plot for "HALLMARK_PI3K_AKT_MTOR_SIGNALING" and "HALLMARK_MTORC1_SIGNALING" between mutant PTEN/mutations in the C2 domain and wild-type PTEN
Supplementary Table S4 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Table S4 presents the list of differentially expressed genes identified between triple-positive and triple-negative Tregs and between triple-positive and other Tregs.
Supplementary Table S3 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Table S3 presents the list of differentially expressed genes identified between triple-positive and triple-negative CD8+ TILs and between triple-positive and other CD8+ TILs.
Supplementary Figure S9 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S9 shows the bioinformatics workflow used to pre-process 10X single-cell sequencing data.
Supplementary Data from Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in Over 5,000 Chinese Patients with Lung Cancer
Authors: Shi Jie , Wang Zhiyu , Zhang Junping , Xu Yaping , Xiao Xiao , Quan Xiangming , Bai Ying , Yang Xia , Ming Zongjuan , Guo Xiaojin , Feng Huijing , Yang Xiaoling , Zhuang Xiaofei , Han Fei , Wang Kai , Shi Yonglei , Lei Yu , Bai Jun , Yang Shuanying
Published: April 2023

Supplementary Tables
Supplementary Table from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms
Authors: Abbott Charles W. , Boyle Sean M. , Pyke Rachel Marty , McDaniel Lee D. , Levy Eric , Navarro Fábio C.P. , Mellacheruvu Dattatreya , Zhang Simo V. , Tan Mengyao , Santiago Rose , Rusan Zeid M. , Milani Pamela , Bartha Gabor , Harris Jason , McClory Rena , Snyder Michael P. , Jang Sekwon , Chen Richard
Published: April 2023

Supplementary Table from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms
Supplementary Figure S4 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S4 shows the distribution of CD39, CD103 and PD1-expressing cells in paired HGSC tumor and ascites samples.
Supplementary Figure S17 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S17 shows the correlation between relevant triple-positive subsets as assessed by immunofluorescence, flow cytometry and single-cell sequencing.
Supplementary Figure S16 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S16 shows the impact of chemotherapy and TIL density on the percentages of relevant TIL subsets.
Supplementary Figure S13 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S13 shows the differential gene expression and TCR repertoire analysis across all subsets of CD8+ TIL isolated from primary HGSC tumor samples.
Supplementary Data from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms
Authors: Abbott Charles W. , Boyle Sean M. , Pyke Rachel Marty , McDaniel Lee D. , Levy Eric , Navarro Fábio C.P. , Mellacheruvu Dattatreya , Zhang Simo V. , Tan Mengyao , Santiago Rose , Rusan Zeid M. , Milani Pamela , Bartha Gabor , Harris Jason , McClory Rena , Snyder Michael P. , Jang Sekwon , Chen Richard
Published: April 2023

Supplementary Data from Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms
Supplementary Figure S10 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S10 shows the marker genes characteristics of T-cell clusters identified by clustering of single-cell gene expression data from TILs.
Supplementary Figure S1 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S1 shows the gating strategies used to identify triple-positive cells by flow cytometry.
Supplemental Figure 5 from Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
Authors: Nagle Veronica L. , Henry Kelly E. , Hertz Charli Ann J. , Graham Maya S. , Campos Carl , Parada Luis F. , Pandit-Taskar Neeta , Schietinger Andrea , Mellinghoff Ingo K. , Lewis Jason S.
Published: April 2023

Distribution of [64Cu]Cu-NOTA-anti-CD8 in the Brain. H&E and autoradiography of striatal, hippocampal and cerebellar sections in the same respective brain. GBM tumor is PDX 160721-1 (n = 3).
Supplementary Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer
Authors: Xia Wei-Xiong , Lv Xing , Liang Hu , Liu Guo-Ying , Sun Rui , Zeng Qi , Li Si-Wei , Mo Hao-Yuan , Han Fei , Luo Dong-Hua , Liu Qing , Shi Meng-Yun , Ye Yan-Fang , Yang Jing , Ke Liang-Ru , Qiang Meng-Yun , Qiu Wen-Ze , Yu Ya-Hui , Liu Kui-Yuan , Huang Xin-Jun , Li Wang-Zhong , Lv Shu-Hui , Cai Zhuo-Chen , Miao Jing-Jing , Guo Ling , Chen Ming-Yuan , Cao Ka-Jia , Wang Lin , Zhao Chong , Huang Pei-Yu , Chen Qiu-Yan , Hua Yi-Jun , Tang Lin-Quan , Qian Chao-Nan , Mai Hai-Qiang , Guo Xiang , Xiang Yan-Qun
Published: April 2023

Supplementary Data
FigureS2 from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer
Authors: Xia Wei-Xiong , Lv Xing , Liang Hu , Liu Guo-Ying , Sun Rui , Zeng Qi , Li Si-Wei , Mo Hao-Yuan , Han Fei , Luo Dong-Hua , Liu Qing , Shi Meng-Yun , Ye Yan-Fang , Yang Jing , Ke Liang-Ru , Qiang Meng-Yun , Qiu Wen-Ze , Yu Ya-Hui , Liu Kui-Yuan , Huang Xin-Jun , Li Wang-Zhong , Lv Shu-Hui , Cai Zhuo-Chen , Miao Jing-Jing , Guo Ling , Chen Ming-Yuan , Cao Ka-Jia , Wang Lin , Zhao Chong , Huang Pei-Yu , Chen Qiu-Yan , Hua Yi-Jun , Tang Lin-Quan , Qian Chao-Nan , Mai Hai-Qiang , Guo Xiang , Xiang Yan-Qun
Published: April 2023

FigureS2
FigureS1 from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer
Authors: Xia Wei-Xiong , Lv Xing , Liang Hu , Liu Guo-Ying , Sun Rui , Zeng Qi , Li Si-Wei , Mo Hao-Yuan , Han Fei , Luo Dong-Hua , Liu Qing , Shi Meng-Yun , Ye Yan-Fang , Yang Jing , Ke Liang-Ru , Qiang Meng-Yun , Qiu Wen-Ze , Yu Ya-Hui , Liu Kui-Yuan , Huang Xin-Jun , Li Wang-Zhong , Lv Shu-Hui , Cai Zhuo-Chen , Miao Jing-Jing , Guo Ling , Chen Ming-Yuan , Cao Ka-Jia , Wang Lin , Zhao Chong , Huang Pei-Yu , Chen Qiu-Yan , Hua Yi-Jun , Tang Lin-Quan , Qian Chao-Nan , Mai Hai-Qiang , Guo Xiang , Xiang Yan-Qun
Published: April 2023

FigureS1
Supplementary Data from Non-invasive Detection of Immunotherapy-Induced Adverse Events
Authors: Ferreira Carolina A. , Heidari Pedram , Ataeinia Bahar , Sinevici Nicoleta , Sise Meghan E. , Colvin Robert B. , Wehrenberg-Klee Eric , Mahmood Umar
Published: April 2023

Supplementary information file containing 9 figures and 3 tables.
Figure S8 from Non-invasive Detection of Immunotherapy-Induced Adverse Events
Authors: Ferreira Carolina A. , Heidari Pedram , Ataeinia Bahar , Sinevici Nicoleta , Sise Meghan E. , Colvin Robert B. , Wehrenberg-Klee Eric , Mahmood Umar
Published: April 2023

Supplementary Figure S8
Supplementary Figure 2 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
Authors: Guardia Cristina , Bianchini Giampaolo , Arpí-LLucià Oriol , Menendez Silvia , Casadevall David , Galbardi Barbara , Dugo Matteo , Servitja Sonia , Montero Juan Carlos , Soria-Jiménez Luis , Sabbaghi MohammadA , Peña Raul , Madoz-Gúrpide Juan , Lloveras Belen , Lluch Ana , Eroles Pilar , Arribas Joaquin , Pandiella Atanasio , Gianni Luca , Rojo Federico , Rovira Ana , Albanell Joan
Published: April 2023

Supplementary Figure 2 shows how NRG1/CAFs, but not normal mammary fibroblasts, mediate trastuzumab resistance in HER2-positive breast cancer cells.
Figure S5 from Non-invasive Detection of Immunotherapy-Induced Adverse Events
Authors: Ferreira Carolina A. , Heidari Pedram , Ataeinia Bahar , Sinevici Nicoleta , Sise Meghan E. , Colvin Robert B. , Wehrenberg-Klee Eric , Mahmood Umar
Published: April 2023

Supplementary Figure S5
Figure S2 from Non-invasive Detection of Immunotherapy-Induced Adverse Events
Authors: Ferreira Carolina A. , Heidari Pedram , Ataeinia Bahar , Sinevici Nicoleta , Sise Meghan E. , Colvin Robert B. , Wehrenberg-Klee Eric , Mahmood Umar
Published: April 2023

Supplementary Figure S2
Supplementary Figure S6 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Authors: Odintsov Igor , Lui Allan J.W. , Sisso Whitney J. , Gladstone Eric , Liu Zebing , Delasos Lukas , Kurth Renate I. , Sisso Exequiel M. , Vojnic Morana , Khodos Inna , Mattar Marissa S. , de Stanchina Elisa , Leland Shawn M. , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary Figure S6 shows additional analysis of seribantumab efficacy in the ovarian cancer PDX OV-10-0050
Supplementary Table S1 from PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates
Authors: Veach Darren R. , Storey Claire M. , Lückerath Katharina , Braun Katharina , von Bodman Christian , Lamminmäki Urpo , Kalidindi Teja , Strand Sven-Erik , Strand Joanna , Altai Mohamed , Damoiseaux Robert , Zanzonico Pat , Benabdallah Nadia , Pankov Dmitry , Scher Howard I. , Scardino Peter , Larson Steven M. , Lilja Hans , McDevitt Michael R. , Thorek Daniel L.J. , Ulmert David
Published: April 2023

Supplementary Table S1